Vilon
- Category
- Bioregulators
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
Vilon is a synthetic dipeptide (Lys-Glu) marketed to support immune recovery and thymic function in aging. Human evidence for these effects is limited and preliminary, and claims about tumor inhibition and cellular aging pathways rely on speculative animal and mechanistic studies. Safety data is limited, and it may interact with high-dose cyclophosphamide in cancer patients. It is not an FDA-approved drug and is available only as unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(8)
Immune system restoration and thymic function support
MediumSupported by human thymus cell culture studies and small open-label clinical reports in elderly patients.
Inhibition of spontaneous tumor growth and lifespan extension
LowExtended lifespan and reduced spontaneous tumors in mice across several studies, no human longevity data.
Epigenetic chromatin reactivation in aging lymphocytes
LowDemonstrated in cultured lymphocytes from elderly donors across multiple studies, no in vivo data yet.
Evidence limits
- Evidence Level
- Limited Evidence
The clinical evidence for Vilon is limited in human studies but extensive in preclinical models. The strongest human evidence comes from the study of elderly cancer patients receiving Vilon as an immunomodulator in complex radical treatment, with preliminary results suggesting improved 2-year survival, prevention of post-operative complications, and improved quality of life (PMID 16075684). The cited long-term human study administered Thymalin and Epithalamin; it does not establish long-term efficacy or safety of isolated Vilon. Preclinical findings are mixed, including increased mammary tumor development in one HER-2/neu mouse model. Other preclinical studies report that Vilon extends lifespan by 20-40% in mice, inhibits spontaneous and carcinogen-induced tumor development, protects thymus and spleen from radiation-induced aging, reactivates chromatin in elderly lymphocytes, upregulates SIRT1 by 6-8x in human stem cells, reduces pro-inflammatory cytokines (TNF, IL-6) in monocyte/macrophage models, improves digestive enzyme activity in aged animals, and reduces TGF-beta and microvessel permeability in chronic renal failure. Major limitations include Khavinson-group origin for nearly all studies, small sample sizes, lack of randomized controlled trials, and absence of formal clinical development outside Russia.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Limited safety data and lack of independent validation
HighPotential immunostimulatory effects in autoimmune conditions
TheoreticalNegative interaction with high-dose cyclophosphamide noted in research
ModerateUnregulated product quality
HighMild transient side effects
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.